{
    "clinical_study": {
        "@rank": "159840", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "Nimotuzumab"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (normal saline)"
            }
        ], 
        "brief_summary": {
            "textblock": "There have been reports suggesting that anti-epidermal growth factor antibody nimotuzumab is\n      advantageous for advanced esophageal cancer patients in combination with chemotherapy or\n      radiotherapy. However, whether maintenance therapy of nimotuzumab provides benefit to\n      advanced esophageal cancer patients is not known."
        }, 
        "brief_title": "Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Stage IV Esophageal Squamous Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Esophageal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "We design this clinical trial to confirm the efficacy of maintenance treatment of\n      nimotuzumab after initial treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient who was confirmed stage IV esophageal carcinoma by pathologic histology or\n             cytology.\n\n          -  The sample size estimate: 20 cases per arm.\n\n          -  Males or females aged \u226518 years, < 75 years.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Life expectancy \u226512\n             weeks.\n\n          -  Males and females should be contraceptive during the period of the trial until 8\n             weeks after the last administration of the drug.\n\n          -  Adequate bone marrow, renal, and liver function are required.\n\n          -  Able to comply with the required protocol and follow-up procedures, and able to\n             receive oral medications.\n\n          -  Institutional review board-approved informed consent will be obtained for every\n             patient before initiation of any trial-specific procedure or treatment.\n\n        Exclusion Criteria:\n\n          -  Any unstable systemic disease (including active infection, uncontrolled hypertension,\n             unstable angina, congestive heart failure, myocardial infarction within the previous\n             year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic\n             disease).\n\n          -  Allergy to anti-EGFR antibody.\n\n          -  Female subjects should not be pregnant or breast-feeding.\n\n          -  Adequate hematological function: Absolute neutrophil count (ANC) \u22651.5 x 109/L, and\n             Platelet count \u2265100 x 109/L. Adequate renal function: Serum creatinine \u2264 1.5 x ULN,\n             or \u2265 50 ml/min. Adequate liver function: total bilirubin < 1.5 x upper limit of\n             normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST)\n             < 2.5 x ULN in the absence of liver metastases, or < 5 x ULN in case of liver\n             metastases.\n\n          -  Patient assessed by the investigator to be unable or unwilling to comply with the\n             requirements of the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02011594", 
            "org_study_id": "ZYTOP1407"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "description": "400mg Q2W intravenously", 
                "intervention_name": "Nimotuzumab", 
                "intervention_type": "Drug", 
                "other_name": "Anti epidermal growth factor receptor antibody h-R3"
            }, 
            {
                "arm_group_label": "Arm B", 
                "description": "Normal saline", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Normal saline"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 5, 2014", 
        "location": [
            {
                "contact": {
                    "email": "doczq.2008@gmail.com", 
                    "last_name": "Qiong Zhao, PhD", 
                    "phone": "0571-87236802"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310003"
                    }, 
                    "name": "The first affiliated hospital, Zhejiang University"
                }, 
                "investigator": {
                    "last_name": "Qiong Zhao, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "doczq.2008@gmail.com", 
                    "last_name": "Qiong Zhao, PhD", 
                    "phone": "0571-87236802"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310003"
                    }, 
                    "name": "Qiong Zhao"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Study of Maintenance Treatment of Nimotuzumab Versus No Maintenance for Advanced Esophageal Carcinoma", 
        "overall_contact": {
            "email": "doczq.2008@gmail.com", 
            "last_name": "Qiong Zhao, PhD", 
            "phone": "0571-87236802"
        }, 
        "overall_official": {
            "affiliation": "First Affiliated Hospital, Zhejiang University", 
            "last_name": "Qiong Zhao, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "PFS (Progression free survival)", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02011594"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Zhejiang University", 
            "investigator_full_name": "Qiong Zhao", 
            "investigator_title": "Chief of Department of Thoracic Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective Response Rate", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Disease control rate (DCR)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Zhejiang University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zhejiang University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}